Current role of endocrine therapy in the management of breast cancer

Beatson G., On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases, Lancet, 2, pp. 104-107, (1896)

Buzdar A., Jonat W., Howell A., Jones S.E., Blomqvist C., Vogel C.L., Eiermann W., Wolter J.M., Azab M., Webster A., Plourde P.V., Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials, Journal of Clinical Oncology, 14, 7, pp. 2000-2011, (1996)

Buzdar A., Jonat W., Howell A., Yin H., Lee D., Significant improved survival with Arimadex (anastrazole) versus megestrol acetate in postmenopausal advanced breast cancer: Updated results of two randomized trials, Proc Am Soc Clin Oncol, 16, (1997)

Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N., Dugardyn J.L., Nasurdi C., Mennel R.G., Cervek J., Fowst C., Polli A., Di Salle E., Arkhipov A., Piscitelli G., Miller L.L., Massimini G., Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial, Journal of Clinical Oncology, 18, 7, pp. 1399-1411, (2000)

Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., Bezwoda W., Gardin G., Gudgeon A., Morgan M., Fornasiero A., Hoffmann W., Michel J., Hatschek T., Tjabbes T., Chaudri H.A., Hornberger U., Trunet P.F., Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate, Journal of Clinical Oncology, 16, 2, pp. 453-461, (1998)

Buzdar A., Douma J., Davidson N., Elledge R., Morgan M., Smith R., Porter L., Nabholtz J., Xiang X., Brady C., Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate, Journal of Clinical Oncology, 19, 14, pp. 3357-3366, (2001)

Bonneterre J., Thurlimann B., Robertson J., Krzakowoski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., Von Euler M., Anastrole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomised group efficacy and tolerability study, J Clin Onco1, 18, pp. 3748-3757, (2000)

Nabolhtz J., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., Von Euler M., Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomised trial, J Clin Oncol, 18, pp. 3758-3767, (2000)

Nabholtz J., Bonneterre J., Buzdar A., Thuerlimann B., Robertson J., Webster A., Steinberg M., Von Euler M., Preliminary results of two multi-center trials comparing the efficacy and toelrability of Arimidex (anastrozole) and tamoxifen in postmenopausal women with advanced breast cancer, Breast Cancer Res Treat, 57, (1999)

Milla-Santos A., Milla L., Rallo L., Et al., Anastrozole versus tamoxifen in hormone dependent advanced breast cancer. A phase II randomised trial, Breast Cancer Res Treat, 64, (2000)

Beatson G., On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases, Lancet, 2, pp. 104-107, (1896)

Buzdar A., Jonat W., Howell A., Jones S.E., Blomqvist C., Vogel C.L., Eiermann W., Wolter J.M., Azab M., Webster A., Plourde P.V., Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials, Journal of Clinical Oncology, 14, 7, pp. 2000-2011, (1996)

Buzdar A., Jonat W., Howell A., Yin H., Lee D., Significant improved survival with Arimadex (anastrazole) versus megestrol acetate in postmenopausal advanced breast cancer: Updated results of two randomized trials, Proc Am Soc Clin Oncol, 16, (1997)

Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N., Dugardyn J.L., Nasurdi C., Mennel R.G., Cervek J., Fowst C., Polli A., Di Salle E., Arkhipov A., Piscitelli G., Miller L.L., Massimini G., Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial, Journal of Clinical Oncology, 18, 7, pp. 1399-1411, (2000)

Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., Bezwoda W., Gardin G., Gudgeon A., Morgan M., Fornasiero A., Hoffmann W., Michel J., Hatschek T., Tjabbes T., Chaudri H.A., Hornberger U., Trunet P.F., Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate, Journal of Clinical Oncology, 16, 2, pp. 453-461, (1998)

Buzdar A., Douma J., Davidson N., Elledge R., Morgan M., Smith R., Porter L., Nabholtz J., Xiang X., Brady C., Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate, Journal of Clinical Oncology, 19, 14, pp. 3357-3366, (2001)

Bonneterre J., Thurlimann B., Robertson J., Krzakowoski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., Von Euler M., Anastrole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomised group efficacy and tolerability study, J Clin Onco1, 18, pp. 3748-3757, (2000)

Nabolhtz J., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., Von Euler M., Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomised trial, J Clin Oncol, 18, pp. 3758-3767, (2000)

Nabholtz J., Bonneterre J., Buzdar A., Thuerlimann B., Robertson J., Webster A., Steinberg M., Von Euler M., Preliminary results of two multi-center trials comparing the efficacy and toelrability of Arimidex (anastrozole) and tamoxifen in postmenopausal women with advanced breast cancer, Breast Cancer Res Treat, 57, (1999)

Milla-Santos A., Milla L., Rallo L., Et al., Anastrozole versus tamoxifen in hormone dependent advanced breast cancer. A phase II randomised trial, Breast Cancer Res Treat, 64, (2000)